Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT01738360
- Locations
- ๐ซ๐ท
CHU de Marseille, Marseille, France
๐ซ๐ทNantes University Hospital, Nantes, France
๐ซ๐ทCHRU de Strasbourg, Strasbourg, France
Study of Arsenic Trioxide in Small Cell Lung Cancer
- Conditions
- Lung CancerCancer of LungPulmonary CancerPulmonary NeoplasmsCarcinoma, Small Cell
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT01470248
- Locations
- ๐บ๐ธ
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2017-12-13
- Target Recruit Count
- 50
- Registration Number
- NCT01428128
- Locations
- ๐บ๐ธ
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Conditions
- Acute Promyelocytic Leukemia With PML-RARA
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 151
- Registration Number
- NCT01409161
- Locations
- ๐บ๐ธ
MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, United States
๐บ๐ธM D Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธMD Anderson Regional Care Center-Katy, Houston, Texas, United States
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT01397734
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Trisenoxยฎ in Women With Metastatic Endometrial Cancer
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01184053
- Locations
- ๐บ๐ธ
North Carolina Cancer Hosptial, UNC, Chapel Hill, North Carolina, United States
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
- Conditions
- Essential ThrombocythemiaPolycythemia VeraPrimary Myelofibrosis
- Interventions
- Dietary Supplement: Ascorbic AcidOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01014546
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 4
- Registration Number
- NCT00985530
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- Conditions
- Myeloid NeoplasmChildhood Acute Promyelocytic Leukemia With PML-RARA
- Interventions
- Other: Diagnostic Laboratory Biomarker Analysis
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 106
- Registration Number
- NCT00866918
- Locations
- ๐บ๐ธ
Overlook Hospital, Summit, New Jersey, United States
๐บ๐ธRutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
๐บ๐ธValley Children's Hospital, Madera, California, United States
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT00850304
- Locations
- ๐ฎ๐ท
Hematology-Oncology and SCT Research Center, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.